	TTER HEALTH® Policy/Guideline	*ae	etna™	
Name:	Nuedexta		Page:	1 of 2
Effective Date: 5/1/2025			Last Review Date:	3/2025
Applica	⊠Illinois	□Florida	🛛 Florida Kids	
Applies to:	⊠New Jersey	□Maryland	⊠Michigan	
	🛛 Pennsylvania Kids	⊠Virginia	Kentucky PRMD	

Intent:

The intent of this policy/guideline is to provide information to the prescribing practitioner outlining the coverage criteria for Nuedexta (dextromethorphan hydrobromide/quinidine sulfate) under the patient's prescription drug benefit.

Description:

Nuedexta is indicated for the treatment of pseudobulbar affect (PBA).

PBA occurs secondary to a variety of otherwise unrelated neurologic conditions, and is characterized by involuntary, sudden, and frequent episodes of laughing and/or crying. PBA episodes typically occur out of proportion or incongruent to the underlying emotional state. PBA is a specific condition, distinct from other types of emotional lability that may occur in patients with neurological disease or injury.

Applicable Drug List:

Nuedexta

Policy/Guideline:

The requested drug will be covered with prior authorization when the following criteria are met:

• The patient has a diagnosis of pseudobulbar affect (PBA)

AND

• The request is NOT for continuation of therapy

OR

• The request is for continuation of therapy

AND

 The patient has achieved or maintained a decrease in pseudobulbar affect (PBA) episodes since starting the requested drug

Approval Duration and Quantity Restrictions:

Approval:

- Initial: 4 months
- Renewal: 12 months

References:

- 1. Nuedexta [package insert]. Aliso Viejo, CA: Avanir Pharmaceuticals, Inc.; June 2019.
- 2. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Waltham, MA: UpToDate, Inc.; 2024. https://online.lexi.com. Accessed February 28, 2024.

	TTER HEALTH® Policy/Guideline	♥aetna ™		
Name:	Nuedexta		Page:	2 of 2
Effective Date: 5/1/2025			Last Review Date:	3/2025
Applies to:	⊠Illinois ⊠New Jersey ⊠Pennsylvania Kids	□Florida □Maryland ⊠Virginia	⊠Florida Kids ⊠Michigan □Kentucky PRMD	

3. Micromedex[®] (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: https://www.micromedexsolutions.com/ (cited: 02/28/2024).

4. Hammond FM, Alexander DN, Cutler AJ, et. Al. PRISM II: An open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury. *BMC Neurol.* 2016;16:89.